Dynamic Changes in Circulating and Tissue Biomarkers and Therapeutic Response to HER2/PD-1 Blockade in Gastric Adenocarcinoma
Blood markers during cancer immunotherapy predict who will respond, helping doctors adjust treatment strategies in real time.
This prospective study characterizes how circulating and tissue biomarkers evolve during dual HER2/PD-1 blockade in gastric cancer, identifying patterns that predict treatment response versus resistance. Results advance biomarker-guided monitoring for combination immunotherapy in HER2-positive gastric adenocarcinoma and point toward adaptive treatment approaches.
What the study was
- Study design
- Prospective biomarker study
- Population
- HER2-positive gastric adenocarcinoma patients receiving dual HER2/PD-1 blockade therapy
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Digestion
Why it surfaced
Prospective liquid biopsy dynamics study in HER2+ gastric cancer linking biomarker evolution to immunotherapy response; addresses resistance prediction in a high-mortality GI malignancy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.